Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst day in a long, long time. On May 1, Lilly reported Q1 earnings. Afterwards ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

The market reacted negatively, with Eli Lilly’s stock dropping 8.56% in pre-market trading. According to InvestingPro analysis, Eli Lilly currently trades above its Fair Value, with an overall ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.